Content area
Full text
Litman RS, Griggs SM, Dowling JJ, Riazi S. Malignant hyperthermia susceptibility and related diseases. Anesthesiology. 2018;128:159-167.
This commentary summarizes recent advances in understanding the genetics and molecular biology underlying malignant hyperthermia (MH) for the purpose of distinguishing patients who can safely receive volatile agents and succinylcholine from those who should receive a trigger-free anesthetic. Mutations in 3 specific genes account for MH susceptibility in approximately 70% of patients. Three main groups of patients are discussed: those with a family history of genetic predisposition to MH, those...